BPC-157 may be less appropriate for those with a history of cancer or active malignancy, individuals uncomfortable with the investigational nature of peptide therapy, people unable to commit to consistent daily administration for 4-8 weeks, those seeking instant results rather than gradual healing, and anyone who cannot source pharmaceutical-grade products from reputable suppliers
A retrospective study evaluating the efficacy and safety of VEGF inhibitor, axitinib plus anti-PD-1 provides improved clinical benefits, with an ORR of 24.5%
This is why many patients prefer a methylation test that measures biochemistry , not just genetics
Contraindications and Drug Interactions Absolute contraindications include Wilsons Disease or other copper metabolism disorders (risk of dangerous copper accumulation), known copper allergy or hypersensitivity (risk of severe allergic reactions), and pregnancy/breastfeeding (no safety data available for systemic use)
Trusted Quality AssuranceManufactured in an ISO 17025 accredited lab for the highest level of product integrity and safety
